Antiviral humoral immunity as biomarker and effector in oncolytic adenovirus TILT-123 therapy.
Journal: Journal for immunotherapy of cancer
•
Abstract
Abstract text is not embedded in this discovery record. Please consult the full-text publication via the source link on the right.
Subjects & Keywords
How to Cite this Article
Arias V, Clubb JH, Kudling TV, et al. (2026). "Antiviral humoral immunity as biomarker and effector in oncolytic adenovirus TILT-123 therapy.". Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2026-016430